Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

Fig. 1

Exposure-response efficacy analysis of nivolumab by tumor type. Vertical lines represent 90 % prediction intervals for each dose level. CI = confidence interval; Cminss = steady-state nivolumab trough concentration; MEL = melanoma; NSCLC = non-small cell lung cancer; Obs Prob = observed probability; OR = objective response; Pred Prob = predicted probability; RCC = renal cell carcinoma

Back to article page